^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    siG12D LODER

    i
    Other names: siG12D LODER, Undisclosed KRAS-loder, KRASG12D-LODER, KRAS loder, antisense K-ras RNA gene therapy, siG12D local drug eluter
    Associations

    News

    Trials
    Company:
    Silexion Therapeutics
    Drug class:
    KRAS inhibitor
    Related drugs:
    Associations

    News

    Trials
    over4years
    [VIRTUAL] A phase II study of siG12D-LODER in combination with chemotherapy in patients with locally advanced pancreatic cancer (PROTACT). (ASCO 2020)
    This phase 2 study was initially designed as a randomized, two arm, open label study of gemcitabine and nab-paclitaxel with or without siG12D-LODER for patients with locally advanced pancreas cancer with planned 40 patients in each arm and primary endpoint of progression-free survival. Trial accrual is anticipated to be completed by December 2020. Research Funding: Silenseed
    Clinical • P2 data • Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12
    |
    gemcitabine • albumin-bound paclitaxel • siG12D LODER